Biogen Idec’s BG-12 Results Up The Ante In The Oral MS Market

The competitive profile of Biogen Idec Inc.’s BG-12 in the highly coveted and burgeoning market for oral multiple sclerosis drugs got a big boost April 21 with the release of better-than-expected additional monotherapy data from the Phase III DEFINE study.